UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 15, 2021

EYENOVIA, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38365 (Commission File Number) 47-1178401

(IRS Employer Identification No.)

295 Madison Avenue, Suite 2400, New York, New York 10017 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (917) 289-1117

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 Par Value	EYEN	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this Chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 and incorporated herein by reference is a corporate update presentation Eyenovia, Inc. intends to use with various investors and analysts.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
<u>99.1</u>	Eyenovia, Inc. corporate update presentation dated March 2021.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYENOVIA, INC.

Date: March 15, 2021

By: /s/ John Gandolfo Name: John Gandolfo

Title: Chief Financial Officer

Exhibit 99.1




Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: volatility and uncertainty in the global economy and financial markets in light of the COVID-19 pandemic and uncertainties arising from the U.S. elections; fluctuations in our financial results; the timing and our ability or the ability of our licensees to submit applications for, obtain and maintain regulatory approvals for our product candidates; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology and potential revenues from licensing transactions; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize certain of our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for certain of our product candidates; risks of our ongoing clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; our ability to raise additional capital; intellectual property risks; and our competitive position.


Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

eyenovia

Investment Highlights



Leadership Team



Late-Stage Ophthalmic Pipeline for US Registration in Markets Valued Over \$12.7 Billion




* Estimate only ¹ Out-licensed to Arctic Vision in Greater China and South Korea ² Estimate from Delive/Insight Presbyspia report; December 2020 ³ Out-licensed to Bausch Health in the US and Canada, and Arctic Vision in Greater China and South Korea ⁴ CHAPERONE oversight and costs assumed by Bausch Health

Potential pipeline expansion activities leveraging Optejet technology are ongoing

eyenovia 癞

Potential Topical US Ophthalmic Market For Platform Technology*



Standard Eyedroppers Have Limited Therapeutic Approaches


Potential overexposure to drug and preservatives

- Conventional droppers can overdose the eye by as much as 300%+1
- · Known to cause ocular and systemic side effects1



Protruding tip may create cross-contamination risk
More than 50% of administrations touch ocular surface²

- More difficult to use with poor compliance
 - Requires head tilting and aiming which may be compromised in pediatric and elderly populations
 - · No dosage reminders or tracking which may lead to missed doses



Optejet Microdose Array Print (MAP) Technology Designed for Optimal Drug Delivery

Precise, Physiological Dosing:

Directly coats the cornea with ~80% less exposure to drug and preservative toxicity (based on 8µL dose).¹ Designed to eliminate drug overflow for a more comfortable patient experience.

Efficacy:

Demonstrated statistical and clinically significant efficacy in . both IOP reduction and pharmacological mydriasis.^{2,3}

Safety:

Low systemic drug absorption and good ocular tolerability.^{3,4}

Non-protruding nozzle for no-touch spray application, potentially minimizing risk of cross contamination seen with traditional eyedroppers.



Abelson, M., 2020. The Hows And Whys Of Pharmacokin asquale L. et al., Clinical Ophthalmology 2018 Wrta D. et al., Presentation at 2019 ASCRS meeting



Ease of Use:

Horizontal drug delivery means no need to tilt the head back. Demonstrated first-time success with both medical professionals and patients.²

Compliance and Adherence:

Can be paired with smart devices to enable dosage reminders and tracking.





Optejet: Significant Clinical Experience and Validation




Five Phase 2 or Phase 3 clinical trials to date featured in dozens of publications and major meetings including ASCRS, AAO, AAOpt, OIS and EYEcelerator.

eyenovia

.



Optejet: Clinical Experience and Validation



Reduced Systemic Levels

Drugs in traditional eyedroppers can enter systemic blood circulation and may cause significant side effects.¹

Microdose delivery of phenylephrine 10% (PE-µD) **was associated with significantly less systemic exposure** than traditional eye drops (PE 10%).²

9 ¹ Muller, M., van der Velpe, N., Jaap, W., van der Cammen, T.; Syncope and falls due to timolol eye drops. BMJ, 2006 April; 332-960-961 ² lanchulev, I. High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine. Ther Deliv, 2018 Jan;9(1):17-27

💽 eyenovia

Optejet: Demonstrated Effectiveness in Multiple Phase 3 Studies

had a superior mydriatic effect compared to either component formulation1 **Microdose Efficacy** MIST-2 MIST-1 Percent of Patients Attaining 6 mm or Greater Pupil Dilation (exploratory analysis) Combined Visits (1, 2, 3) 35 Minutes Post-Administration vs Baseline Mean Pupil Diameter (mm) (+/-SD) **Primary End Point** 6 4 3 93 2 1 * p=0.018 50 20 35 65 ≥6 mm Pupil Dilation 80 120 Time Point Right Eve - 1-Wirta, D. Presented at ASCRS Annual Meeting, 2019, San Diego CA .

leyenovia

Microdosing a fixed combination of tropicamide-phenylephrine

Estimated Gross Margins Based on \$100/Month Price¹

82% - 94%


Next-Generation Ophthalmic Therapeutics

- Eyenovia's microdose therapeutics follow the 505(b)(2) registration pathway and are not currently regulated as medical devices or drug-device combinations
- · The FDA categorizes the Optejet as a container closure system

Eyenovia Products Aim to Provide Competitive Pharmaceutical Margins:


- · All pipeline products are Eyenovia's own proprietary micro-formulations
- Eyenovia currently owns the pharma-economics of the entire prescription value chain
- · MicroLine has strong potential as a cash-pay cosmeceutical

MicroLine for Presbyopia




Pilocarpine: Dual Action Mechanism Improves Near Vision

- > Pilocarpine is a Miotic (cholinergic) and has a clinically established dual action mechanism
- Accommodation and extended-depth of focus
- > Optimized profile through microdose









MicroLine: Phase 3 Program

- > Two double-masked, placebo-controlled, cross-over superiority trials
 - Phase 3 (microdosed pilocarpine dose 1, dose 2 and placebo)
- > Primary endpoint: binocular distance corrected near visual acuity
- First patient enrolled in VISION 1: December 2020



MicroLine Compared with the Standard Presbyopia Drop



16

Late Stage Presbyopia Competitive Landscape

Trial	Compound	Company	3-line gain	2-line gain	Safety	Completion date	NDA Status
gemini-1 Pili	Pilo 1.25%	ALLERGAN/ ABBVIE	MET (40 – 55 YO)		Headache No serious AEs	Q3 2020	
GEMINI-2 PIII	Pilo 1.25%	ALLERGAN/ ABBVIE	MET (40 – 55 YO)		Headache No serious AEs	Q3 2020	Filed 2/2021
NEAR 1 Pill	Pilo+	ORASIS				Recruiting 45 – 64 YO Q2 2021	
NEAR 2 Pill	Pilo+	ORASIS				Recruiting 45 – 64 YO Q2 2021	
VISION 1 PIII	Pilo 1%, 2%	EYEN				Recruiting 40 – 60 YO Study results expected Q2 2021	

17 Source: Company press releases and clinicaltrials go

MicroPine for Progressive Myopia



Progressive of Myopic Maculopathy

Affects ~25M children in the US alone, with ~5M considered to be at high risk⁴

- Back-of-the-eye disease
- Mostly begins in early childhood, with a genetic link to myopic parents¹
- Pathologic elongation of sclera/retina which can lead to significant morbidity and visual sequelae²
 - Retinal detachment
 - Myopic retinopathy
 - Vision loss
 - Quality of life
- Currently, no FDA-approved drug therapies to slow myopia progression
- Atropine may slow myopia progression by 60% or more³

¹ Eye and CenterLiens. 2004: 30 ² Chia A, Chua WH, Cheung YB, et al. Attopine for the treatment of hildhood Myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01%, doses (Attopine for the Treatment of Myopia 2). Ophthalmology 2012;119:347-354 ⁴ Theophenois C. Myopia Provalence and Risk Factors in Children. Clinical Central International Content Postation Survey. Annual Social and Economic Surveyance and Risk Factors in Children. Clinical Central International Content Postation Survey. Annual Social and Economic Surveyance and Risk Factors in Children. Clinical Central International Content Postation Surveyance and Risk Factors in Children Clinical Central International Content Postation Surveyance and Risk Factors in Children Clinical Central Centra

Strategic Partnerships to Potentially Extend Commercial Reach

VISION	BAUSCH-Health
Arctic Vision	Bausch Health
/alidating partnership for the development and commercialization of MicroPine and MicroLine	Strategic partnership for the development and commercialization of MicroPine
Jpfront payment: \$4M	Upfront payment: \$10M
Potential milestone payments and reimbursed levelopment costs: \$41.75M	Potential milestone payments and reimbursed development costs: \$50M (Reimbursed development costs associated with Phase 3 CHAPERONE trial to begin immediately)
Commercial supply terms or royalties: mid-single digits	Royalties on gross profit: mid-single digit to mid-teen percentages
erritory: Greater China (mainland China, Hong Kong,	Territory: US and Canada
Iacau and Taiwan) and South Korea appacted population estimated at approx. more than 8x the US ¹	US impacted population with high myopia estimated at approx. $3M^{2,3}$

Future Licensing Opportunities



MydCombi for Mydriasis

- > Pharmacologic mydriasis (pupil dilation) is part of the comprehensive eye exam
 - Estimated 80 million office-based comprehensive and diabetic eye exams and 4 million ophthalmic surgical dilations performed annually in the United States
 - Essential for diabetic retinopathy, glaucoma and retina disease screening
 - An estimated \$250 million US market opportunity¹
- Places technology at the initial point-of-care with prescribers (ophthalmologists and optometrists)
- No direct contact increases patient safety by reducing potential cross contamination associated with the use of shared dilating drops in OD/OPH offices
- No anticipated reimbursement hurdles; expect to sell directly to ophthalmology and optometry practices
- NDA accepted March 2021










- If approved, the only fixed combination of the two leading mydriatic medications in the US
 - Administered with the push of a button, saving up to ten minutes of technician time¹
- Touch-free, comfortable application with fewer than 1% of patients experiencing stinging discomfort²
- Lower drug and preservative exposure, including systemic absorption of phenylephrine, which can be problematic in hypertensive patients^{2,3}
- Reliable in numerous patient practices. More than 9 out of 10 patients achieved clinically significant mydriasis at 35 minutes postdosage²

eyenovia

¹Denion E. et al, A.5-Minute Interval between Two Dilating Eye Drops Increases Their Effect. Optom Vis Sci. 2017 Aug ²Wirta, D. Presented at ASCRS Annual Meeting, 2019, San Diego CA ³ Abelson M. 2020. The Hows And Whys Of Pharmacolinentics. Reviewe@Onthhalmology.com: accessed 11/3/20

22

MydCombi has a Superior Mydriatic Effect vs. Single Agents







Office & Surgical Use

Mydriasis >6 mm achieved in >93% of patients at 35 minutes post-dosage which is clinically meaningful for both office retinal exam and surgical dilation

23 Presented by S. Rathi et al, American Academy of Optometry Annual Meeting, 2020



MydCombi Launch Expenses: A Fraction of a Typical Ophthalmic Drug Launch

Expense	Typical Launch	MydCombi Launch	Rationale
Sales Force	100 FTE @ \$150K = \$15M	11 FTE @ \$150K = \$1.7M	Only need to call on group practices; no need for ongoing visits
Managed Care Department	8 FTE @ \$150K = \$1.2M	0	No third-party payer; no formulary (cash to office)
Rebates and Logistics	8 – 12% of sales plus 2 FTE	9% of sales	Single specialty pharmacy partner
Promotion	\$25M	\$2M	Very little "noise" to break through; no direct-to-patient element; targeted education for technicians
Total	~\$50M	~\$5M	

Technology that has Multiple Layers of IP, Clinical and Regulatory Protection

Worldwide patents are granted on the dispenser, the drop size, velocity of delivery and data capture from the base unit are in effect until late 2031 Provisional patents have been filed on the Gen 2 dispenser and if approved will bring protection through 2040 An additional barrier is the clinical and regulatory hurdles a competitor would have to meet to gain approval for an 8µ dose

25

Financial Snapshot

Nasdaq:	EYEN
Common Shares Outstanding	24.9M
Equity Grants Outstanding Under Stock Plans	3.5M
Warrants	2.3M
Fully Diluted Shares	30.7M
Cash	\$22.9M
Debt	None

All figures as of September 30, 20

Board of Directors



